Should You Stop Oral Naltrexone When Starting Vivitrol?
No, you do not need to stop oral naltrexone before initiating Vivitrol (extended-release injectable naltrexone), as pretreatment with oral naltrexone is not required. However, understanding the pharmacokinetics and clinical context is essential for safe transition.
Key FDA Guidance on Transition
The FDA-approved prescribing information for Vivitrol explicitly states: "Pretreatment with oral naltrexone is not required before using VIVITROL" 1. This is the most direct answer to your question—there is no mandatory discontinuation period or bridging requirement when switching formulations.
Important Clinical Context
Why No Discontinuation is Needed
Both oral naltrexone and Vivitrol contain the same active ingredient (naltrexone) and work through identical mechanisms—competitive antagonism at mu-opioid receptors. The key difference is pharmacokinetic:
- Oral naltrexone: Half-life of 4 hours (active metabolite 6-β-naltrexol has 13-hour half-life), with antagonist effects persisting 2-3 days after stopping 2
- Vivitrol (IM depot): Provides sustained naltrexone levels for approximately 4 weeks 1
Since both formulations provide opioid receptor blockade, there is no therapeutic gap or safety concern with direct transition.
Critical Safety Requirement: Opioid-Free Status
The crucial consideration is not whether to stop oral naltrexone, but rather ensuring the patient is opioid-free. Prior to initiating Vivitrol, patients must have an opioid-free duration of minimum 7-10 days to avoid precipitating severe opioid withdrawal 1. This requirement applies regardless of whether the patient was previously on oral naltrexone or is naltrexone-naïve.
Practical Transition Approach
If Patient is Currently on Oral Naltrexone:
- Verify opioid-free status for at least 7-10 days (this should already be established if they're tolerating oral naltrexone)
- Administer Vivitrol at the standard 380 mg IM gluteal dose
- No washout period needed between last oral dose and first injection
If Transitioning from Buprenorphine or Methadone:
The FDA label notes that patients switching from opioid agonist therapy may experience severe precipitated withdrawal, with vulnerability to withdrawal symptoms for as long as 2 weeks 1. This is a different clinical scenario requiring careful management with non-opioid medications for withdrawal symptoms.
Common Clinical Pitfall
The main error is confusing the requirement to be opioid-free (which applies to all patients starting naltrexone) with a need to discontinue oral naltrexone specifically. The opioid-free requirement exists to prevent precipitated withdrawal from residual opioid agonists, not from naltrexone itself (which is an antagonist).
Perioperative Context
While not directly relevant to routine transition, it's worth noting that if surgery requiring opioids is planned, oral naltrexone should be held 2-3 days and Vivitrol should be held 24-30 days after the last injection 2. This demonstrates the extended duration of action of the depot formulation.
Adherence Advantage
The transition from oral to injectable formulation addresses a major limitation—adherence. Research shows that many patients discontinue oral naltrexone prematurely (50% at 1 month, 71% at 6 months), while depot formulations have better retention rates 3, 4. This makes the direct transition to Vivitrol clinically advantageous when appropriate.